These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37046778)

  • 1. Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials.
    Ciardiello D; Napolitano S; Famiglietti V; Esposito L; De Falco V; Di Liello A; Avallone A; Maiello E; Pietrantonio F; Cremolini C; Zampino MG; Fazio N; Troiani T; Martinelli E; Ciardiello F; Martini G
    Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial.
    Ciardiello D; Martinelli E; Troiani T; Mauri G; Rossini D; Martini G; Napolitano S; Famiglietti V; Del Tufo S; Masi G; Santini D; Avallone A; Pietrantonio F; Lonardi S; Di Maio M; Zampino MG; Fazio N; Bardelli A; Siena S; Cremolini C; Sartore-Bianchi A; Ciardiello F
    JAMA Netw Open; 2024 Apr; 7(4):e245635. PubMed ID: 38592721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
    Martinelli E; Martini G; Famiglietti V; Troiani T; Napolitano S; Pietrantonio F; Ciardiello D; Terminiello M; Borrelli C; Vitiello PP; De Braud F; Morano F; Avallone A; Normanno N; Nappi A; Maiello E; Latiano T; Falcone A; Cremolini C; Rossini D; Santabarbara G; Pinto C; Santini D; Cardone C; Zanaletti N; Di Liello A; Renato D; Esposito L; Marrone F; Ciardiello F
    JAMA Oncol; 2021 Oct; 7(10):1529-1535. PubMed ID: 34382998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma ctDNA RAS status selects patients for anti-EGFR treatment rechallenge in metastatic colorectal cancer: a meta-analysis.
    Vlachou MS; Mauri D; Zarkavelis G; Ntellas P; Tagkas C; Gkoura S; Pentheroudakis G
    Exp Oncol; 2021 Sep; 43(3):252-256. PubMed ID: 34591420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies.
    Kataoka K; Yamada T; Shiozawa M; Takase N; Ito K; Yamazaki K; Watanabe J; Kudo T; Suto T; Matsumoto T; Murata K; Suwa Y; Boku S; Yasui H; Matsuhashi N; Maeda A; Sugimoto K; Matsumoto Y; Yokota M; Fredebohm J; Mori K; Ikeda M
    J Anus Rectum Colon; 2024; 8(2):132-136. PubMed ID: 38689780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival.
    Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Pietrantonio F; Avallone A; Maiello E; Cremolini C; Troiani T; Martinelli E; Ciardiello F; Martini G
    Clin Colorectal Cancer; 2022 Jun; 21(2):141-148. PubMed ID: 35101346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients.
    Mariani S; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Donisi C; Persano M; Pinna G; Cimbro E; Parrino A; Spanu D; Pretta A; Lai E; Liscia N; Lupi A; Giglio E; Palomba G; Casula M; Pisano M; Palmieri G; Scartozzi M
    Front Oncol; 2022; 12():852583. PubMed ID: 35530345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
    Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
    JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin Toxicity as Predictor of Survival in Refractory Patients with
    Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Normanno N; Avallone A; Latiano T; Maiello E; Pietrantonio F; Cremolini C; Santabarbara G; Pinto C; Troiani T; Martinelli E; Ciardiello F; Martini G
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
    van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
    J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial.
    Germani MM; Vetere G; Giordano M; Ciracì P; Capone I; Tamborini E; Conca E; Busico A; Pietrantonio F; Piva VM; Boccaccino A; Simionato F; Bortolot M; Manca P; Lonardi S; Conca V; Borelli B; Carullo M; Del Re M; Fontanini G; Rossini D; Cremolini C
    Front Oncol; 2023; 13():1307545. PubMed ID: 38406172
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Sunakawa Y; Nakamura M; Ishizaki M; Kataoka M; Satake H; Kitazono M; Yanagisawa H; Kawamoto Y; Kuramochi H; Ohori H; Nakamura M; Maeda F; Komeno C; Sonezaki T; Takeuchi M; Fujii M; Yoshino T; Tsuji A; Ichikawa W
    JCO Precis Oncol; 2020 Nov; 4():898-911. PubMed ID: 35050760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
    van Helden EJ; Angus L; Menke-van der Houven van Oordt CW; Heideman DAM; Boon E; van Es SC; Radema SA; van Herpen CML; de Groot DJA; de Vries EGE; Jansen MPHM; Sleijfer S; Verheul HMW
    Mol Oncol; 2019 Nov; 13(11):2361-2374. PubMed ID: 31350822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge.
    Chennamadhavuni A; Kasi PM
    Front Oncol; 2022; 12():847299. PubMed ID: 35837097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.
    Sartore-Bianchi A; Pietrantonio F; Lonardi S; Mussolin B; Rua F; Crisafulli G; Bartolini A; Fenocchio E; Amatu A; Manca P; Bergamo F; Tosi F; Mauri G; Ambrosini M; Daniel F; Torri V; Vanzulli A; Regge D; Cappello G; Marchiò C; Berrino E; Sapino A; Marsoni S; Siena S; Bardelli A
    Nat Med; 2022 Aug; 28(8):1612-1618. PubMed ID: 35915157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.
    Moretto R; Rossini D; Capone I; Boccaccino A; Perrone F; Tamborini E; Masi G; Antoniotti C; Marmorino F; Conca V; Borelli B; Martignetti A; Pecora I; Simionato F; Cupini S; Ambrosini M; Manca P; Pietrantonio F; Falcone A; Cremolini C
    Clin Colorectal Cancer; 2021 Dec; 20(4):314-317. PubMed ID: 34364814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Undetectable
    Bouchahda M; Saffroy R; Karaboué A; Hamelin J; Innominato P; Saliba F; Lévi F; Bosselut N; Lemoine A
    JCO Precis Oncol; 2020; 4():. PubMed ID: 33015528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with
    Martini G; Ciardiello D; Napolitano S; Martinelli E; Troiani T; Latiano TP; Avallone A; Normanno N; Di Maio M; Maiello E; Ciardiello F
    Front Oncol; 2023; 13():1069370. PubMed ID: 36860319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment.
    Wang F; Huang YS; Wu HX; Wang ZX; Jin Y; Yao YC; Chen YX; Zhao Q; Chen S; He MM; Luo HY; Qiu MZ; Wang DS; Wang FH; Xu M; Li YH; Xu RH
    Gut; 2022 Jul; 71(7):1340-1349. PubMed ID: 34489309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti-Epidermal Growth Factor Receptor Therapy.
    Maurel J; Alonso V; Escudero P; Fernández-Martos C; Salud A; Méndez M; Gallego J; Rodriguez JR; Martín-Richard M; Fernández-Plana J; Manzano H; Méndez JC; Zanui M; Falcó E; Gil-Raga M; Aparicio J; Feliu J; García-Albéniz X; Torres F; Rojo F; Bellosillo B; Mendiola M; Fernández V; Reig O; Claes B; Maertens G; Sablon E; Jacobs B; Montagut C
    JCO Precis Oncol; 2019 Dec; 3():1-16. PubMed ID: 35100697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.